Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emraclidine PK and Safety in Healthy Elderly Subjects
NCT07219030Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of emraclidine in schizophrenia (6 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Adverse Events, Number of Participants with Clinical Significant Change From Baseline in Vital Sign Measurements and 22 more. Started Oct 2025; status: recruiting.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07219030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219030.